Hypoxia-inducible factor 1α modulates interstitial pneumonia-mediated lung cancer progression

• Published in: Journal of translational medicine 2023-11, Vol.21 (1), p.857-857, Article 857
• Main Authors: Shimoji, Kiyofumi, Nakashima, Taku, Masuda, Takeshi, Namba, Masashi, Sakamoto, Shinjiro, Yamaguchi, Kakuhiro, Horimasu, Yasushi, Mimae, Takahiro, Miyamoto, Shintaro, Iwamoto, Hiroshi, Fujitaka, Kazunori, Hamada, Hironobu, Okada, Morihito, Hattori, Noboru
• Format: Article
• Language: English
• Subjects: Alpha subunit; Animal models; Animals; Ascorbic Acid; Bar codes; Bioinformatics; Bleomycin; Fibrosis; Genes; Humans; Hypoxia; Hypoxia - pathology; Hypoxia-inducible factor; Hypoxia-inducible factor 1; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Hypoxia-inducible factor 1a; Hypoxia-inducible factors; Immunosuppressive agents; Interstitial pneumonia; Kinases; Laboratory animals; Lung - pathology; Lung cancer; Lung diseases; Lung Diseases, Interstitial - complications; Lung Diseases, Interstitial - metabolism; Lung Diseases, Interstitial - pathology; Lung Neoplasms - genetics; Lung transplantation; Mice; Patients; Pneumonia; Pulmonary Fibrosis - pathology; Radiation therapy; Sequence analysis; Signal transduction; Therapeutic applications; Therapeutic targets; Tumor Microenvironment; Tumors
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04756-6

The prognosis of patients with lung cancer accompanied by interstitial pneumonia is poorer than that of patients with lung cancer but without interstitial pneumonia. Moreover, the available therapeutic interventions for lung cancer patients with interstitial pneumonia are limited. Therefore, a new treatment strategy for these patients is required. The aim of the present study was to investigate the pathophysiological relationship between interstitial pneumonia and lung cancer and explore potential therapeutic agents. A novel hybrid murine model of lung cancer with interstitial pneumonia was established via bleomycin-induced pulmonary fibrosis followed by orthotopic lung cancer cell transplantation into the lungs. Changes in tumor progression, lung fibrosis, RNA expression, cytokine levels, and tumor microenvironment in the lung cancer with interstitial pneumonia model were investigated, and therapeutic agents were examined. Additionally, clinical data and samples from patients with lung cancer accompanied by interstitial pneumonia were analyzed to explore the potential clinical significance of the findings. In the lung cancer with interstitial pneumonia model, accelerated tumor growth was observed based on an altered tumor microenvironment. RNA sequencing analysis revealed upregulation of the hypoxia-inducible factor 1 signaling pathway. These findings were consistent with those obtained for human samples. Moreover, we explored whether ascorbic acid could be an alternative treatment for lung cancer with interstitial pneumonia to avoid the disadvantages of hypoxia-inducible factor 1 inhibitors. Ascorbic acid successfully downregulated the hypoxia-inducible factor 1 signaling pathway and inhibited tumor progression and lung fibrosis. The hypoxia-inducible factor 1 pathway is critical in lung cancer with interstitial pneumonia and could be a therapeutic target for mitigating interstitial pneumonia-mediated lung cancer progression.